Quick Facts

• Assists with Diagnostic Procedures: Supports the examination of the inner eye structures.
• Facilitates Pupil Dilation (Mydriasis): Induces temporary widening of the pupil.
• Supports Temporary Eye Muscle Relaxation (Cycloplegia): Aids in assessing the eye's refractive state.

---

What Mydriaticum Stulln Supports: Main Applications and Contributory Effects

Mydriaticum Stulln is an ophthalmic preparation intended for use in specialized eye care settings. Its primary application is to facilitate comprehensive diagnostic examinations of the eye by helping to achieve an expanded pupil size. This temporary effect, known as mydriasis, is required to allow the healthcare professional to observe the lens, vitreous humor, and retina, which are the structures at the back of the eye. A dilated pupil supports a more detailed evaluation during a fundus examination.

This medication also contributes to the temporary relaxation of the ciliary muscle, a related effect known as cycloplegia. This action can be a factor in determining a patient's need for corrective lenses (refraction assessment) as it temporarily prevents the eye from adjusting its focus on close objects. The use of this drug is generally confined to specific procedures performed by an eye care specialist.

Its use is limited to the applications described and must be administered under the direction of a qualified practitioner. It is important to note that this preparation supports procedural requirements; it does not constitute a definitive treatment for chronic eye conditions.

---

This section details the official population eligibility and non-eligibility rules for Mydriaticum Stulln (Tropicamide ophthalmic solution), based strictly on government regulatory documents.

---

Eligibility Scope

Category	Regulatory Statement
Populations for whom use is allowed	Adults and older children for diagnostic procedures.
Populations for whom use is not recommended	Small infants (e.g., those under 3 months of age) and pregnant women, unless clearly needed.
Populations for whom use is contraindicated	Patients with known or suspected narrow-angle glaucoma or hypersensitivity to the formulation.

---

Age-Related and Condition-Specific Rules

Age-Related Eligibility:

• Small Infants: Use is not recommended due to increased risk of central nervous system (CNS) disturbances.
• Pediatric Patients: Must be used with extreme caution, especially in children with Down syndrome or spastic paralysis.
• Older Adults: Permitted, but intraocular pressure (IOP) and angle depth must be checked prior to use, as required by regulatory guidance.

Conditional Use Restrictions:

• Systemic Conditions: Use requires great caution in patients with conditions like cardiac disorders, hyperthyroidism, or diabetes mellitus.
• Pregnancy/Lactation: Safety is not established; caution is advised for both pregnant and nursing mothers.

---

Connection to the Overall Eligibility Profile

Regulatory documentation establishes absolute prohibitions for certain ocular risks, such as narrow-angle glaucoma, and mandates explicit caution for vulnerable groups, including infants and patients with pre-existing systemic disorders. These rules strictly define the population for whom the medicine is considered eligible for diagnostic use.

Mydriaticum Stulln contains tropicamide and phenylephrine, and its components may interact with other medicines, particularly those with similar pharmacological effects. It is critical to inform your doctor about all prescription and non-prescription drugs, herbal remedies, and supplements you are using.

️ Potentially Significant Interactions

Type of Interaction	Potentially Interacting Medicines	Effect of Interaction
Increased Risk of Systemic Side Effects	Anticholinergic drugs (e.g., certain antihistamines, tricyclic antidepressants, antispasmodics)	The risk of side effects like dry mouth, constipation, or confusion may be amplified.
Increased Blood Pressure	Monoamine Oxidase Inhibitors (MAOIs) (e.g., tranylcypromine, phenelzine) or Tricyclic Antidepressants	The risk of a significant increase in blood pressure (hypertensive crisis) due to the phenylephrine component may be heightened.
Reduced Efficacy	Cholinergic agonists/miotics (e.g., pilocarpine, carbachol, echothiophate iodide)	The mydriatic (pupil-dilating) effect of Mydriaticum Stulln may counteract the pupil-constricting and pressure-lowering effects of these glaucoma treatments.

Other Considerations

• Other Sympathomimetics: Combining with other adrenaline-like agents (sympathomimetics) should be approached with caution due to the risk of additive cardiovascular and central nervous system effects.
• Inhalational Anesthetics: The use of Mydriaticum Stulln prior to surgery requiring potent inhalational anesthetics (such as halothane) may increase the risk of certain cardiovascular adverse effects.

Always ensure your eye care professional is fully aware of your complete medical history and current medication regimen.

How Mydriaticum Stulln Works: Mechanism of Action

The active ingredient, Tropicamide, functions as a short-acting parasympatholytic agent, meaning it temporarily interrupts signals from the parasympathetic nervous system specifically within the eye.

---

Molecular Target and Competitive Antagonism

The drug's action begins at the molecular level by blocking the Muscarinic Acetylcholine Receptors ( M3 AChRs) found on the smooth muscles of the iris and ciliary body. Tropicamide acts as a competitive antagonist, reversibly binding to these receptors to physically stop the endogenous neurotransmitter, Acetylcholine ( ACh), from initiating muscle contraction.

---

Functional Shift and Dual Physiological Effect

Blocking the cholinergic signal removes the input responsible for muscle movement, creating a functional paralysis of the iris sphincter and ciliary muscle. This leads directly to the dual physiological consequences of mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation), as the parasympathetic drive is inhibited, leaving the opposing sympathetic system unopposed.

---

Mechanism-Driven Rapid Onset and Limitations

Tropicamide is highly lipophilic, a property that facilitates its rapid penetration across the cornea to reach the target receptors quickly, leading to a fast onset of effect. However, the presence of melanin in highly pigmented irides can physically bind the drug, effectively lowering the available concentration for receptor blockade and potentially slowing the rate of receptor occupancy.

Mydriaticum Stulln (Tropicamide) is an ophthalmic solution administered into the eye to cause temporary pupil dilation (mydriasis) and paralysis of the focusing muscle (cycloplegia), primarily for diagnostic eye examinations like cycloplegic refraction and fundus examination. This medication is typically administered by a healthcare professional in a clinical setting.

Administration Guidelines

To ensure proper use and minimize systemic absorption, follow these general steps upon instillation:

1. Preparation: Remove contact lenses before administration. Wash hands thoroughly before handling the eye drops.
2. Instillation: Tilt the head back and create a small pouch by gently pulling the lower eyelid down. Instill the prescribed number of drops into this space. Avoid touching the dropper tip to the eye or any other surface to prevent contamination.
3. Post-Instillation: Gently close the eye for a few minutes. Immediately after dropping, apply light finger pressure to the tear duct (inner corner of the eye next to the nose) for two to three minutes. This action helps limit the amount of medication absorbed into the bloodstream.
4. Hands Washing: Wash your hands again after use, especially when administering to children, to prevent accidental ingestion.

Indication	Strength/Concentration	Usual Dosage
Cycloplegic Refraction	1% solution	1-2 drops, repeated in 5 minutes
Fundus Examination	0.5% solution	1-2 drops 15-20 minutes before examination

Note: Dosage and concentration may be adjusted by the healthcare provider based on the patient's age and eye pigmentation, as heavily pigmented irides may require a higher strength or additional drops.

---

Post-Treatment Precautions

After receiving Mydriaticum Stulln, expect blurred vision and increased sensitivity to light (photophobia). These effects can last for several hours, with complete recovery from dilation potentially taking up to 24 hours. Patients must not drive or operate machinery until their vision has fully recovered. Wear sunglasses outdoors to protect the eyes from bright light during dilation.

Mydriaticum Stulln: Recent Clinical Evidence

The body of research for Mydriaticum Stulln (Tropicamide) primarily consists of short-term, controlled clinical trials, meta-analyses, and systematic reviews. This evidence base was examined during the evaluation of the medicine's role as a diagnostic agent, focusing on its ability to temporarily achieve mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation), which are necessary for certain eye examinations.

Evidence for Use in Pupillary Dilation (Mydriasis)

Research exploring pupillary dilation was studied in randomized controlled trials and systematic reviews, which focus on short-term ocular effects. These studies examined the degree of pupillary diameter achieved and the sufficiency of dilation needed for a fundus examination. Study populations included adults, children, and adolescents, with some trials addressing the measured changes in groups with dark-colored irides and in patients with conditions such as diabetes. Data show patterns that suggest the maximum pupillary diameter was typically observed within 25 to 30 minutes following administration, with the dilated state generally observed to reverse between four and eight hours.

Evidence for Use in Paralysis of Accommodation (Cycloplegia)

The research exploring cycloplegia involves comparative efficacy studies and systematic reviews. This evidence base was evaluated to determine the drug’s role in temporarily relaxing the eye's focusing muscle during refraction measurements. Studies report that the maximum cycloplegic effect was typically measured 20 to 30 minutes after the drops were administered. Comparative trials noted that the resulting refractive error measurements were generally similar to those obtained with certain other cycloplegic agents.

Evidence in Specific Populations and Research Gaps

Research has been conducted to monitor outcomes in populations whose ocular characteristics may differ, including studies evaluated in both children and infants to examine measured changes in young patients. Furthermore, the consistency of findings remains limited regarding its use as the sole cycloplegic agent in infants or pediatric patients presenting with high degrees of hyperopia or strabismus, suggesting that subgroup findings are uncertain. The research base focuses on short-term physiological imbalance. Consequently, long-term effects are not fully established, as the existing evidence concentrates on the transient effects required for a procedure, and the follow-up durations were limited.

Common questions about Mydriaticum Stulln (FAQ)

---

Q: What is the active substance in Mydriaticum Stulln?

Mydriaticum Stulln contains the active substance tropicamide. According to official product information, this is the ingredient responsible for the medicine's effect on the eye. The concentration of this active substance is a key element in its intended clinical use.

---

Q: How long does the effect of Mydriaticum Stulln typically last?

Regulatory documents indicate that the effect of this eye medicine on the pupil dilation (mydriasis) generally lasts for a short period. The duration can vary slightly depending on the concentration used. The effects are usually temporary and intended for a medical examination or procedure.

---

Q: Is Mydriaticum Stulln safe to use during pregnancy?

Official product information states that Mydriaticum Stulln should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. This careful consideration is particularly important during the first three months. Use during pregnancy is typically considered following a review of the potential benefits and risks by the prescriber.

---

Q: What should I do if I miss a dose of Mydriaticum Stulln?

This medication is typically administered by a healthcare professional just before a planned medical examination or procedure, so missed doses are usually not a concern for the patient. If this medication is being used at home, following the application schedule is important. Questions about a missed dose should be directed to the prescribing healthcare provider, as instructions vary.

---

Q: Can I drive or operate machinery after using Mydriaticum Stulln?

According to the official product information, Mydriaticum Stulln causes temporary vision problems, including blurred vision and sensitivity to light. The official documentation advises against driving or operating machinery until vision has fully recovered. Due to visual impairment, it is generally recommended to arrange transportation or have an escort after the application.

---

Q: Can children use Mydriaticum Stulln?

Official regulatory information states that this medicine can be used in children. For infants and younger children, careful consideration of the dose and concentration is necessary, as outlined in the official product information. The appropriate concentration and dosage will be determined by a healthcare professional.

---

Q: How should Mydriaticum Stulln be stored?

Official information advises that this medicine should be stored below 25°C. It is important to keep the eye drops in their original container to protect them from light and moisture. Reviewing and following the storage directions on the product labeling helps maintain the medicine's integrity.

How to Store and Dispose of Mydriaticum Stulln? — Official Regulatory Information

The storage and disposal requirements for Mydriaticum Stulln (Tropicamide/Phenylephrine ophthalmic drops) are defined by government regulatory documents to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, specifically 15°C to 25°C (59°F to 77°F). Do not refrigerate or freeze.
Protection	Protect from light and keep the container tightly closed.
Child Safety	Keep out of the reach of children.

Handling and Stability

The sterile solution must be handled carefully: do not touch the dropper tip to any surface to prevent contamination. The medicine has a limited in-use stability period: the contents must be discarded 4 weeks (one month) after first opening the bottle, even if some medicine remains.